Susoctocog Alfa

證據等級: L5

預測適應症: 10 個

Susoctocog Alfa: Toward Hemophilia (Acquired Factor VIII Deficiency) — Original Indication Not on Record

One-Sentence Summary

Susoctocog alfa (DrugBank DB11606) is a recombinant, B-domain-deleted porcine-sequence Factor VIII product; its originally documented indication is not recorded in the current data source. The TxGNN model’s highest-evidenced prediction points to Hemophilia (specifically Acquired Hemophilia A), supported by 1 clinical trial and 20 publications, including real-world cohort studies and reviews. Note: TxGNN’s top-ranked predictions by raw score (platelet release disorder, pseudo-von Willebrand disease, Glanzmann thrombasthenia) have zero supporting trials or literature and are flagged in the model’s own rationale as likely knowledge-graph proximity artifacts — they are excluded from the primary recommendation below.

Quick Overview

Item	Content
Original Indication	Not recorded in current data source (data gap)
Predicted New Indication	Hemophilia (Acquired Hemophilia A)
TxGNN Prediction Score	99.74%
Evidence Level	L3 (Observational studies / reviews; no completed RCT on file)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism-of-action data is currently a data gap for this record. However, the literature evidence collected alongside the prediction is unambiguous: susoctocog alfa is described as “a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product” (Burness & Scott, Drugs 2016, PMID 27098420) used to restore hemostatic FVIII activity in patients whose endogenous FVIII is neutralized by autoantibodies.

This maps directly onto the pathophysiology of Acquired Hemophilia A (AHA) — a bleeding disorder caused by autoantibody inhibition of Factor VIII — which is exactly the clinical population described across the 20 associated publications and the ongoing post-marketing surveillance trial (NCT06461533, Japan). In other words, the TxGNN signal for “hemophilia” is not a novel mechanistic leap; it is a knowledge-graph rediscovery of the drug’s already-established, literature-documented use. For Denmark, the open question is therefore not mechanistic plausibility but market entry/registration status, since the drug currently holds zero Danish marketing authorisations.

By contrast, TxGNN’s numerically higher-scoring predictions (primary platelet release disorder, pseudo-von Willebrand disease, Glanzmann thrombasthenia) involve platelet-function or platelet-membrane defects that are mechanistically unrelated to FVIII replacement. The evidence pack’s own rationale explicitly attributes these to graph-embedding proximity among “bleeding tendency” nodes rather than genuine mechanistic or clinical signal, and no trials or literature support any of them. They are therefore not treated as actionable candidates in this report.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06461533	N/A	Recruiting	25	Japanese all-case post-marketing surveillance of IV susoctocog alfa (OBIZER) in patients with bleeding events of Acquired Hemophilia A; monitors side effects and treatment outcomes.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27098420	2016	Review	Drugs	Comprehensive review of susoctocog alfa (Obizur); references a completed multinational Phase II/III trial (n=28 evaluable) showing effective, generally well-tolerated control of serious bleeds in AHA.
32698943	2020	Cohort	Blood Transfusion	Italian multicentre real-world registry of 9 elderly AHA patients treated with susoctocog alfa.
39158833	2024	Cohort (Phase II/III, NCT04580407)	Int J Hematol	Japanese open-label study of efficacy/safety of recombinant porcine FVIII in AHA; primary endpoint met for severe bleeding control.
39245591	2024	Review	Rev Med Interne	2024 update on acquired hemophilia diagnosis and treatment landscape.
40812597	2025	PK study	J Thromb Haemost	Pharmacokinetic strategies for precise FVIII control with susoctocog alfa in AHA.
37510704	2023	Case series / Review	J Clin Med	Surgery and prophylaxis with susoctocog alfa in AHA; case series and literature review.
38066923	2023	Review	Hematology ASH Educ Program	Diagnosis and laboratory monitoring of AHA, relevant to treatment-monitoring context.
41436689	2025	Case report	CEN Case Reports	Successful hemodialysis initiation in AHA managed with susoctocog alfa plus emicizumab.
34011555	2023	Case report	Eur J Hosp Pharm	High-risk bleeding treated with susoctocog alfa in an AHA patient with concurrent SARS-CoV-2 infection.
35501873	2022	Case report	J Med Case Rep	AHA with coexisting lupus anticoagulant.

Denmark Market Information

Susoctocog alfa currently holds no marketing authorisation in Denmark — neither a national Laegemiddelstyrelsen licence nor an EMA centralised authorisation is on record (0 of 0 licenses).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-interaction data are not currently available in this evidence pack; obtaining the manufacturer’s TFDA/EMA-approved SmPC is a blocking requirement before any safety pre-assessment (S1) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale:

Mechanistic plausibility is well supported by 20 publications and 1 ongoing surveillance trial confirming the drug’s established FVIII-replacement role in Acquired Hemophilia A (Evidence Level L3), but there is no completed Phase 3 RCT on file, no Danish marketing authorisation, and no accessible SmPC safety data — a blocking gap for further evaluation.

To proceed, the following is needed:

SmPC/TFDA warnings, contraindications, and drug-interaction data (Blocking gap DG001)
Confirmed mechanism-of-action documentation from DrugBank or manufacturer labeling (High-priority gap DG002)
Clarification of the drug’s original approved indication(s), currently unrecorded in this data source
Assessment of the Danish regulatory pathway for a product with no existing EU/EMA-linked Danish licence
Deprioritize or formally rule out the platelet-disorder / von Willebrand / Glanzmann thrombasthenia predictions, which lack any supporting evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.